Fulcrum Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Oltmans Curtis Gale | Chief Legal Officer | Sale | 3,452 | $12.92 | $44,600 | 10,252 | Dec 15, 2025 |
| RA Capital Healthcare Fund LP | — | Sale | 2,706,397 | $14.28 | $38,647,349 | 6,145,682 | Dec 8, 2025 |
| Gould Robert J | — | Sale | 15,000 | $11.03 | $165,450 | 484,864 | Nov 19, 2025 |
| Tourangeau Greg | Principal Accounting Officer | Sale | 498 | $5.06 | $2,520 | 14,062 | May 8, 2025 |
| Shah Rajeev M. | — | Other | 8,500,000 | — | — | 3,109,704 | Aug 21, 2024 |
| Sapir Alex | See Remarks | Option Exercise | 150,000 | $3.27 | $490,500 | 193,360 | Jul 3, 2024 |
| Tourangeau Greg | Principal Accounting Officer | Sale | 236 | $7.76 | $1,831 | 11,571 | May 7, 2024 |
| Tourangeau Greg | Vice President, Finance | Sale | 4,884 | $11.72 | $57,240 | 11,807 | Mar 8, 2024 |
| Sapir Alex | See Remarks | Purchase | 43,360 | $11.35 | $492,136 | 43,360 | Mar 4, 2024 |
| Tourangeau Greg | Principal Accounting Officer | Sale | 210 | $3.31 | $695 | 15,992 | May 10, 2023 |
| RA CAPITAL MANAGEMENT, L.P. | — | Purchase | 1,923,076 | $13.00 | $24,999,988 | 11,609,704 | Jan 20, 2023 |
| Gould Robert J | Interim President & CEO | Sale | 6,766 | $15.00 | $101,490 | 499,864 | Jan 13, 2023 |
| RA Capital Healthcare Fund LP | — | Purchase | 122,334 | $7.03 | $860,008 | 9,628,259 | Jan 4, 2023 |
| Kolchinsky Peter | — | Purchase | 4,089 | $5.99 | $24,493 | 9,505,925 | Dec 27, 2022 |
| Kolchinsky Peter | — | Purchase | 98,787 | $5.90 | $582,843 | 9,501,836 | Dec 19, 2022 |
| RA CAPITAL MANAGEMENT, L.P. | — | Purchase | 237,029 | $5.50 | $1,303,660 | 8,061,629 | Dec 16, 2022 |
| TRV GP III, LLC | — | Other | 2,000,000 | — | — | 1,962,202 | Dec 13, 2022 |
| Gould Robert J | — | Option Exercise | 71,435 | $7.84 | $560,050 | 578,065 | Jun 7, 2022 |
| Gould Robert J | — | Option Exercise | 25,551 | $7.84 | $200,320 | 532,181 | Jun 2, 2022 |
| Tourangeau Greg | Controller | Award / Grant | 3,250 | — | — | 16,202 | May 6, 2022 |
| Gould Robert J | — | Option Exercise | 5,631 | $7.84 | $44,147 | 512,261 | Apr 7, 2022 |
| Gould Robert J | — | Option Exercise | 52,552 | $7.84 | $412,008 | 559,182 | Apr 1, 2022 |
| Oltmans Curtis Gale | SVP, General Counsel | Gift | 1,088 | — | — | 1,248 | Dec 17, 2021 |
| LEVIN MARK J | — | Other | 1,000,000 | — | — | 3,962,202 | Nov 10, 2021 |
| STARR KEVIN P | — | Other | 1,000,000 | — | — | 3,962,202 | Nov 10, 2021 |
| STARR KEVIN P | — | Other | 1,000,000 | — | — | 4,962,202 | Sep 22, 2021 |
| LEVIN MARK J | — | Other | 1,000,000 | — | — | 4,962,202 | Sep 22, 2021 |
| Stuart Bryan | See Remarks | Sale | 28,000 | $23.75 | $665,000 | — | Aug 11, 2021 |
| Moxham Christopher | Chief Scientific Officer | Option Exercise | 20,714 | $7.84 | $162,398 | 20,714 | Aug 10, 2021 |
| Morabito Christopher | Chief Medical Officer | Purchase | 1,100 | $9.16 | $10,076 | 1,100 | Jun 28, 2021 |
| Thomson Peter G. | VP Finance & Accounting | Purchase | 2,300 | $9.00 | $20,700 | 2,300 | Jun 28, 2021 |
| Oltmans Curtis Gale | SVP, General Counsel | Purchase | 1,088 | $9.01 | $9,803 | 1,088 | Jun 28, 2021 |
| GERAGHTY JAMES A | — | Purchase | 10,000 | $9.16 | $91,600 | 90,714 | Jun 28, 2021 |
| Gould Robert J | See Remarks | Sale | 789 | $12.43 | $9,807 | 506,630 | Mar 15, 2021 |
| Thomson Peter G. | VP Finance & Accounting | Sale | 5,000 | $14.72 | $73,600 | 15,212 | Feb 22, 2021 |
| Gould Robert J | See Remarks | Sale | 1,673 | $14.56 | $24,359 | 516,630 | Feb 16, 2021 |
| Thomson Peter G. | VP Finance & Accounting | Sale | 6,607 | $14.00 | $92,498 | 15,212 | Jan 21, 2021 |
| Gould Robert J | See Remarks | Sale | 10,000 | $12.08 | $120,800 | 524,845 | Jan 20, 2021 |
| Wallace Owen B. | Chief Scientific Officer | Option Exercise | 6,350 | $7.84 | $49,784 | 133,438 | Sep 14, 2020 |
| Gould Robert J | See Remarks | Sale | 2,500 | $20.00 | $50,000 | 534,845 | Jul 8, 2020 |
| Wallace Owen B. | Chief Scientific Officer | Sale | 2,951 | $20.00 | $59,020 | 127,088 | Jul 8, 2020 |
| Cadavid Diego | SVP Clinical Development | Sale | 1,071 | $18.30 | $19,599 | 65,714 | Jul 1, 2020 |
| Wallace Owen B. | Chief Scientific Officer | Option Exercise | 141 | $7.84 | $1,105 | 127,229 | Jun 30, 2020 |
| Gould Robert J | See Remarks | Sale | 2,500 | $20.80 | $52,000 | 537,345 | Jun 25, 2020 |
| Cadavid Diego | SVP Clinical Development | Option Exercise | 1,459 | $4.83 | $7,047 | 68,244 | Jun 25, 2020 |
| Cadavid Diego | SVP Clinical Development | Sale | 401 | $22.00 | $8,822 | 66,785 | Jun 10, 2020 |
| Gould Robert J | See Remarks | Sale | 156 | $20.00 | $3,120 | 539,845 | Jun 9, 2020 |
| Cadavid Diego | SVP Clinical Development | Option Exercise | 451 | $4.83 | $2,178 | 67,236 | Jun 5, 2020 |
| Gould Robert J | See Remarks | Sale | 3,433 | $20.17 | $69,244 | 540,001 | Jun 5, 2020 |
| Gould Robert J | See Remarks | Sale | 1,300 | $20.04 | $26,052 | 543,434 | Jun 3, 2020 |